Cullinan Therapeutics, Inc. (NASDAQ: CGEM)
$12.0600
-0.1400 ( -2.51% ) 76.6K
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Market Data
Open
$12.0600
Previous close
$12.2000
Volume
76.6K
Market cap
$698.73M
Day range
$11.1100 - $13.1100
52 week range
$10.0000 - $30.1886
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | May 15, 2024 |
10-q | Quarterly Reports | 62 | May 15, 2024 |
4 | Insider transactions | 1 | May 08, 2024 |
4 | Insider transactions | 1 | Apr 30, 2024 |
3 | Insider transactions | 2 | Apr 30, 2024 |
8-k | 8K-related | 12 | Apr 29, 2024 |
8-k | 8K-related | 56 | Apr 16, 2024 |
3 | Insider transactions | 2 | Apr 02, 2024 |
10-k | Annual reports | 118 | Mar 14, 2024 |
8-k | 8K-related | 14 | Mar 14, 2024 |